182 related articles for article (PubMed ID: 24342747)
1. Infliximab vs adalimumab for Crohn's disease: perhaps too early to call it a tie.
Dassopoulos T; Sorrentino D
Clin Gastroenterol Hepatol; 2014 May; 12(5):818-20. PubMed ID: 24342747
[No Abstract] [Full Text] [Related]
2. Infliximab vs adalimumab for Crohn's disease.
Dhillon AS; Harris AW
Clin Gastroenterol Hepatol; 2015 Jan; 13(1):210. PubMed ID: 24954114
[No Abstract] [Full Text] [Related]
3. Comparative effectiveness of infliximab and adalimumab for Crohn's disease.
Osterman MT; Haynes K; Delzell E; Zhang J; Bewtra M; Brensinger C; Chen L; Xie F; Curtis JR; Lewis JD
Clin Gastroenterol Hepatol; 2014 May; 12(5):811-817.e3. PubMed ID: 23811254
[TBL] [Abstract][Full Text] [Related]
4. Reply: To PMID 23811254.
Osterman MT
Clin Gastroenterol Hepatol; 2015 Jan; 13(1):210-1. PubMed ID: 25151256
[No Abstract] [Full Text] [Related]
5. Effectiveness of infliximab after adalimumab failure in Crohn's disease.
Chaparro M; Andreu M; Barreiro-de Acosta M; García-Planella E; Ricart E; Domènech E; Esteve M; Merino O; Nos P; Peñalva M; Gisbert JP
World J Gastroenterol; 2012 Oct; 18(37):5219-24. PubMed ID: 23066316
[TBL] [Abstract][Full Text] [Related]
6. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
Doecke JD; Hartnell F; Bampton P; Bell S; Mahy G; Grover Z; Lewindon P; Jones LV; Sewell K; Krishnaprasad K; Prosser R; Marr D; Fischer J; R Thomas G; Tehan JV; Ding NS; Cooke SE; Moss K; Sechi A; De Cruz P; Grafton R; Connor SJ; Lawrance IC; Gearry RB; Andrews JM; Radford-Smith GL;
Aliment Pharmacol Ther; 2017 Feb; 45(4):542-552. PubMed ID: 27995633
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
8. The classics in perspective.
Panés J; Ghosh S
Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
[No Abstract] [Full Text] [Related]
9. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
[TBL] [Abstract][Full Text] [Related]
10. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
Heidemann J; Kucharzik T
Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
[No Abstract] [Full Text] [Related]
11. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
Da W; Zhu J; Wang L; Lu Y
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
[TBL] [Abstract][Full Text] [Related]
12. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
Lichtenstein GR
Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
[No Abstract] [Full Text] [Related]
13. PANTS extension study: how best to use anti-TNF drugs in Crohn's disease.
Parkes GC; Hedin CRH
Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):489-491. PubMed ID: 38640938
[No Abstract] [Full Text] [Related]
14. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy.
Mishkin DS; Van Deinse W; Becker JM; Farraye FA
Inflamm Bowel Dis; 2006 Aug; 12(8):827-8. PubMed ID: 16917239
[No Abstract] [Full Text] [Related]
15. [Biological compounds in the treatment of Crohn's disease].
Dinari G
Harefuah; 2001 Apr; 140(4):316-8. PubMed ID: 11303396
[No Abstract] [Full Text] [Related]
16. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.
Choi GK; Collins SD; Greer DP; Warren L; Dowson G; Clark T; Hamlin PJ; Ford AC
J Crohns Colitis; 2014 May; 8(5):375-83. PubMed ID: 24129316
[TBL] [Abstract][Full Text] [Related]
17. Reply: To PMID 24530602.
Regueiro M; Kip KE; Baidoo L; Swoger JM; Schraut W
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1407. PubMed ID: 24614332
[No Abstract] [Full Text] [Related]
18. Anti-TNF antibody therapy in Crohn's disease: the risk of a switch.
Ricart E; Ordás I; Panés J
Gut; 2012 Feb; 61(2):169-70. PubMed ID: 22068167
[No Abstract] [Full Text] [Related]
19. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
20. Commentary: infliximab or adalimumab in Crohn's disease?
Sprakes MB; Hamlin PJ
Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
[No Abstract] [Full Text] [Related]
[Next] [New Search]
